BPC 157, a 15-amino-acid peptide found naturally in human stomach juice, demonstrates broad healing properties by protecting cells, blood vessel linings, and actively directing blood flow toward injuries.
3-part cytoprotectionBPC 157 protects cells, blood vessel linings, and actively controls blood vessel function at injury sites — extending the stomach cytoprotection concept to the whole body
What the researchers found
BPC 157, a pentadecapeptide (15 amino acids) native to human gastric juice, demonstrated a three-part cytoprotective mechanism: (1) stomach cell protection, (2) endothelium (blood vessel lining) protection, and (3) active blood vessel function control. After perforating injuries, BPC 157 activated blood vessels to grow toward the defect. After vessel obstruction, it activated collateral vessels to bypass the blockage.
The peptide prevented and reversed thrombosis in both arterial and venous models, attenuated bleeding and low platelet counts after amputation, and counteracted the effects of both L-NAME and L-arginine on the nitric oxide system. It has already entered clinical trials for ulcerative colitis and multiple sclerosis.
Why it matters
BPC 157 extends the concept of 'cytoprotection' — originally limited to stomach lining protection — into a whole-body healing principle. Its ability to protect endothelium, redirect blood vessel growth toward injuries, activate collateral circulation around blockages, and influence thrombosis represents a remarkably broad therapeutic profile for a single peptide. The fact that it's native to human gastric juice and has advanced to clinical trials makes it one of the more intriguing peptides in translational development.
The numbers in context
15 amino acid peptide · Native to human gastric juice · 3-part cytoprotective mechanism · Clinical trials for ulcerative colitis and multiple sclerosis · Thrombosis reversal in arterial and venous models
How the study worked
This is a review article summarizing the authors' extensive body of research on BPC 157. It synthesizes findings from multiple preclinical animal studies examining BPC 157's effects on gastrointestinal healing, vascular protection, thrombosis, bleeding, and organ lesion repair. The review presents a conceptual framework (three-part cytoprotection) for understanding BPC 157's mechanism of action.
Who was studied
Review of preclinical animal studies; references ongoing human clinical trials for ulcerative colitis and multiple sclerosis
What this study cannot tell us
The vast majority of evidence comes from animal studies conducted primarily by this single research group. The review is written by BPC 157's discoverers, introducing potential bias. While clinical trials are mentioned (ulcerative colitis, multiple sclerosis), published human efficacy data from these trials is not presented in this abstract. The broad range of claimed benefits across many organ systems is unusual and warrants independent replication. The mechanisms underlying BPC 157's diverse effects are not fully elucidated.
How to read the evidence
This is a narrative review by the principal BPC 157 research group, summarizing primarily their own preclinical animal data. While clinical trials are referenced, human efficacy data is not presented. The evidence is promising but comes predominantly from one research group.
When this study was published
Published in 2018, this review captures the state of BPC 157 research at that time. The status of the referenced clinical trials for ulcerative colitis and multiple sclerosis would need to be checked for current progress.
The bigger picture
BPC 157 occupies a unique position in peptide research — it's one of the few body-protective peptides that has shown effects across nearly every organ system tested in animals. If its clinical trial results confirm even a fraction of the preclinical findings, it could establish a new category of peptide therapeutics based on the principle of 'cytoprotection' — essentially enhancing the body's own healing mechanisms rather than targeting a specific disease pathway.
Questions still open
- Will the clinical trials for ulcerative colitis and multiple sclerosis confirm the broad healing effects seen in animal studies?
- What is the specific molecular mechanism by which BPC 157 directs blood vessel growth and activates collateral circulation?
- Can independent research groups replicate the wide range of beneficial effects reported by BPC 157's discoverers?
Common questions
What is BPC 157 and where does it come from?
Is BPC 157 approved as a medication?
Read the original research
Novel Cytoprotective Mediator, Stable Gastric Pentadecapeptide BPC 157. Vascular Recruitment and Gastrointestinal Tract Healing.
Current pharmaceutical design, 24(18), 1990-2001
Citation
Sikiric, Predrag; Rucman, Rudolf; Turkovic, Branko; Sever, Marko; Klicek, Robert; Radic, Bozo; Drmic, Domagoj; Stupnisek, Mirjana; Misic, Marija; Vuletic, Lovorka Batelja; Pavlov, Katarina Horvat; Barisic, Ivan; Kokot, Antonio; Peklic, Marina; Strbe, Sanja; Blagaic, Alenka Boban; Tvrdeic, Ante; Rokotov, Dinko Stancic; Vrcic, Hrvoje; Staresinic, Mario; Seiwerth, Sven. (2018). Novel Cytoprotective Mediator, Stable Gastric Pentadecapeptide BPC 157. Vascular Recruitment and Gastrointestinal Tract Healing.. Current pharmaceutical design, 24(18), 1990-2001. https://doi.org/10.2174/1381612824666180608101119